TYPE OF REVIEW | NUMBER OF AUTHORS | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
MAs (n = 129) | SRs (n = 136) | 1–4 (n = 140) | > 4 (n = 125) | |||||||
ITEM | Mean | 95% CI | Mean | 95% CI | p | Mean | 95% CI | Mean | 95% CI | p |
Title | 91.86 | 87.14–96.58 | 94.53 | 91.02–98.02 | 0.655 | 90.43 | 85.76–95.08 | 96.4 | 93.18–99.61 | 0.028* |
Objectives | 84.5 | 79.77–89.21 | 85.4 | 80.91–89.88 | 0.771 | 82.62 | 77.85–87.39 | 87.6 | 83.29–91.90 | 0.153 |
Eligibility criteria | 64.73 | 57.55–71.90 | 62.41 | 55.25–69.56 | 0.68 | 60.28 | 53.35–67.21 | 67.2 | 59.81–74.58 | 0.14 |
Information sources | 58.53 | 51.29–65.75 | 65.69 | 58.76–72.62 | 0.139 | 64.18 | 57.41–70.95 | 60 | 52.54–67.45 | 0.428 |
Risk of bias | 21.71 | 14.83–28.57 | 10.95 | 6.28–15.61 | 0.030* | 12.41 | 7.22–17.59 | 20.4 | 13.83–26.96 | 0.035* |
Included studies | 73.26 | 67.69–78.81 | 65.81 | 60.47–71.14 | 0.038* | 63.21 | 57.85–68.57 | 76.4 | 71.05–81.74 | 0.001** |
Synthesis of results | 84.5 | 79.65–89.34 | 69.71 | 63.61–75.79 | < 0.001*** | 73.76 | 67.99–79.52 | 80.4 | 74.90–85.89 | 0.106 |
Description of the effect | 85.27 | 80.23–90.30 | 69.34 | 63.09–75.59 | < 0.001*** | 75.53 | 69.76–81.30 | 78.8 | 72.82–84.77 | 0.375 |
Strengths and limitations of the evidence | 27.91 | 20.77–35.03 | 36.86 | 29.74–43.97 | 0.054 | 31.91 | 25.00–38.82 | 33.2 | 25.74–40.65 | 0.81 |
Interpretation | 93.02 | 89.13–96.91 | 93.07 | 89.96–96.17 | 0.506 | 92.55 | 89.11–95.99 | 93.6 | 90.04–97.15 | 0.564 |
Funding and conflict of interest | 0 | – | 0 | – | 1 | 0 | – | 0 | – | 1 |
Registration | 0.78 | 0.00–2.30 | 0 | – | 0.303 | 0 | – | 0.8 | 0.00–2.38 | 0.288 |
Total PRISMA-A score | 57.11 | 55.26–58.95 | 54.41 | 52.69–56.12 | 0.026* | 53.77 | 52.06–55.48 | 57.89 | 56.08–59.69 | < 0.001*** |